MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer
- Conditions
- bowel cancercolon carcinoma10017991
- Registration Number
- NL-OMON47411
- Lead Sponsor
- Antoni van Leeuwenhoek Ziekenhuis
- Brief Summary
Trial is onging in other countries
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
1. Written informed consent (+ TR (translational research)) must be given according to ICH/GCP and national/local regulations
2. Written documentation of BRAF-like signature CC, including BRAFm and BRAFwt, as determined by the validated assay of Agendia
3. written documentation of KRAS and BRAF mutational status
4. Age * 18 years
5. Histologically proven and measurable (RECIST criteria v.1.1) metastatic adenocarcinoma of the colon not in a previously irradiated area, treated with one or two lines of standard of care therapy, including BRAF inhibitors, for locally advanced disease and metastatic disease
6. WHO performance status of 0-1
7.Life expectancy > 3 months allowing adequate follow up of toxicity evaluation and antitumor activity
8. Negative urine pregnancy test for female patients with childbearing potential
1. Any treatment with investigational drugs, including BRAF inhibitors, within 28 days prior to receiving the first dose of investigational treatment
2. Symptomatic or untreated leptomeningeal disease;3. Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 4 weeks) are allowed to enroll. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids;4. Impairment of gastrointestinal (GI) function or GI disease (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, any condition inducing malabsorption, small bowel resection);5. Other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection;6. Known allergy or any other adverse reaction to any of the drugs or to any related compound;7. Women who are pregnant or breast feeding;8. Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms);9. Patients who have undergone any major surgery within the last 2 weeks prior to starting study drug or who would not have fully recovered from previous surgery;10. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;11. Patients with a known history of hepatitis B or C;12. Known hypersensitivity to study drug or excipients
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Efficacy, as defined as doubling of progression free survival (PFS) of<br /><br>vinorelbine treatment in patients with BRAF-like colon cancer. This means that<br /><br>by vinorelbine treatment the rate of progression at 6 weeks drops to 25%. </p><br>
- Secondary Outcome Measures
Name Time Method <p>* To characterize the safety and tolerability of vinorelbine, as assessed by<br /><br>the incidence and severity of adverse events.<br /><br>* To assess efficacy of vinorelbine, as measured by overall response rate,<br /><br>duration of response, time to response and overall survival (OS).<br /><br>* To compare the activity of vinorelbine in patients with KRAS mutant, BRAF<br /><br>wildtype, BRAF-like colon cancer vs. KRAS wildtype, BRAF mutant, BRAF-like<br /><br>colon cancer.<br /><br>* To explore determinants (gene alteration/expression) of response to<br /><br>vinorelbine, as measured by baseline molecular status (mutation/ expression) in<br /><br>tumor tissue of potential predictive markers of tumor response.<br /><br>* To explore the potential mechanism of resistance to vinorelbine, as measured<br /><br>by gene alterations/expression profiles (i.e. baseline, relapse) in tumor<br /><br>tissue upon progression. </p><br>